US Funding Uncertainty Will Squeeze Life Sciences Yet Spark Resilience
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
22 Jun 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$53.00
1.1% overvalued intrinsic discount16 Aug
US$53.60
1Y
-28.1%7D
6.3%